XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3

Restructuring, Impairment, and Related Charges, Net (Tables)

6 Months Ended

Sep. 30, 2024

Restructuring and Related Activities [Abstract]

Restructuring, Impairment, and Related Costs

Restructuring, impairment, and related charges, net for the three months ended September 30, 2024 and 2023 consisted of the following:

			Three Months Ended September 30, 2024
(In millions)			U.S. Pharmaceutical (1)						Prescription Technology Solutions						Medical-Surgical Solutions (2)						International						Corporate						Total
Severance and employee-related costs, net			$	1					$	—					$	144					$	—					$	4					$	149
Exit and other-related costs (3)			—						—						3						(1)						10						12
Asset impairments and accelerated depreciation			63						1						—						—						9						73
Total			$	64					$	1					$	147					$	(1)					$	23					$	234

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s U.S. Pharmaceutical segment, including an inventory impairment of $63 million within "Cost of sales" in the Condensed Consolidated Statement of Operations.

(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment.

(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

			Three Months Ended September 30, 2023
(In millions)			U.S. Pharmaceutical						Prescription Technology Solutions (1)						Medical-Surgical Solutions						International						Corporate						Total
Severance and employee-related costs, net			$	8					$	—					$	—					$	2					$	—					$	10
Exit and other-related costs (2)			1						3						4						4						6						18
Asset impairments and accelerated depreciation			—						—						—						—						—						—
Total			$	9					$	3					$	4					$	6					$	6					$	28

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions.

(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

Restructuring, impairment, and related charges, net for the six months ended September 30, 2024 and 2023 consisted of the following:

			Six Months Ended September 30, 2024
(In millions)			U.S. Pharmaceutical (1)						Prescription Technology Solutions						Medical-Surgical Solutions (2)						International						Corporate						Total
Severance and employee-related costs, net			$	1					$	—					$	144					$	—					$	3					$	148
Exit and other-related costs (3)			—						3						6						(1)						12						20
Asset impairments and accelerated depreciation			64						2						—						1						9						76
Total			$	65					$	5					$	150					$	—					$	24					$	244

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s U.S. Pharmaceutical segment, including an inventory impairment of $63 million within "Cost of sales" in the Condensed Consolidated Statement of Operations.

(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment.

(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

			Six Months Ended September 30, 2023
(In millions)			U.S. Pharmaceutical						Prescription Technology Solutions (1)						Medical-Surgical Solutions						International						Corporate (1)						Total
Severance and employee-related costs, net			$	9					$	—					$	—					$	2					$	1					$	12
Exit and other-related costs (2)			2						5						6						9						18						40
Asset impairments and accelerated depreciation			—						—						—						1						27						28
Total			$	11					$	5					$	6					$	12					$	46					$	80

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions.

(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

Schedule of Restructuring and Asset Impairment Charges

The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the six months ended September 30, 2024:

(In millions)			U.S. Pharmaceutical						Prescription Technology Solutions						Medical-Surgical Solutions						International						Corporate						Total
Balance, March 31, 2024 (1)			$	18					$	5					$	1					$	10					$	21					$	55
Restructuring, impairment, and related charges, net			65						5						150						—						24						244
Non-cash charges			(64)						(2)						—						(1)						(9)						(76)
Cash payments			(4)						(2)						(7)						(2)						(10)						(25)
Other (2)			(1)						(2)						—						(5)						(2)						(10)
Balance, September 30, 2024 (3)			$	14					$	4					$	144					$	2					$	24					$	188

(1)As of March 31, 2024, the total reserve balance was $55 million, of which $24 million was recorded in “Other accrued liabilities” and $31 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.

(2)Other primarily includes cumulative translation adjustments within International, and transfers to certain other liabilities, including Canadian retail disposal group reserves.

(3)As of September 30, 2024, the total reserve balance was $188 million, of which $160 million was recorded in “Other accrued liabilities” and $28 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.

X

- References

No definition available.

+ Details

Name:	us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482017/420-10-50-1

+ Details

Name:	us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4.b.2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482017/420-10-50-1

+ Details

Name:	us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration